The National Cancer Institute (NCI) and the National Institute of Biomedical Imaging and Bioengineering (NIBIB) of the National Institutes of Health (NIH), have awarded physIQ a contract to develop an AI-based COVID-19 Decompensation Index (CDI) Digital Biomarker to address the rapid decline of high-risk COVID-19 patients, according to a press release. Currently, high-risk COVID-19 patients and their providers, are finding out too late that in the disease continuum they are getting sicker and need urgent care.
The new early warning system under development could allow providers to intervene sooner when a COVID-19 patient is clinically surveilled from home and begins to worsen. Rather than relying on point measurements, such as temperature and SpO2, that are known to be lagging or insensitive indicators of COVID-19 decompensation, continuous multi-parameter vital signs will be used to establish a targeted biomarker for COVID-19.
“Despite the technological advances and attention paid to COVID-19, the healthcare community is still monitoring patient vitals the very same way as we did in the 1800s,” said Steven Steinhubl, MD, Director of Digital Medicine at Scripps Translational Science Institute (STSI) and a physIQ advisor. “With the advances in digital technology, AI and wearable biosensors, we can deliver personalized medicine remotely giving caregivers new tools to proactively address this pandemic. For that reason alone, this decision by the NIH has the potential to have a monumental impact on our healthcare system and how we manage COVID-19 patients.”
PhysIQ will develop and validate a CDI algorithm that builds off existing wearable biosensor-derived analytics generated by physIQ’s pinpointIQ end-to-end cloud platform for continuous monitoring of physiology. The data will be gathered through a clinical study of COVID-19 positive patients in collaboration with University of Illinois Hospital and Health Sciences System (UI Health) and build upon work already in-place for monitoring COVID-19 patients convalescing at home.
The study is designed to capture data from a large, diverse population to investigate CDI performance differences among subgroups based on sex/gender and racial/ethnic characteristics. This project will not only enable the development and validation of the CDI, it will also collect rich clinical data correlative with outcomes and symptomology related to COVID-19 infection.
“We are honored to have been selected by the NIH to pursue such a worthy cause in such challenging times,” said Gary Conkright, CEO of physIQ. “This is a culmination of many years spent in the pursuit of developing a clinical grade product to address serious medical conditions, without taking shortcuts, that has the ability to monitor the most complicated machine in the world, the human body.”